Skip to main content
. 2025 Dec 8;18:7381–7393. doi: 10.2147/IJGM.S549714

Table 2.

Comparison of Clinicopathological Features of NSMP and Non-NSMP Endometrial Cancer

Clinicopathological Features NSMP (n = 159) Non-NSMP (n = 404) P Values
Age (years)
 <55, n (%) 65(40.9%) 158(39.1%) 0.703 (χ2= 0.150)
 ≥55, n (%) 94(59.1%) 246(60.9%)
Reproductive history
 No, n (%) 8(5.0%) 8(2.0%) 0.085 (χ2= 3.847)
 Yes, n (%) 151(95.0%) 396(98.0%)
Menopause
 No, n (%) 55(34.6%) 119(29.5%) 0.267 (χ2= 1.244)
 Yes, n (%) 104(65.4%) 281(69.6%)
Histological type
 Endometrioid carcinoma, n (%) 151(95.0%) 332(82.3%) 0.012 (χ2= 14.073)
 Serous carcinoma, n (%) 1(0.6%) 32(7.9%)
 Clear cell carcinoma, n (%) 3(1.9%) 8(2.0%)
 Squamous cell carcinoma, n (%) 1(0.6%) 1(0.2%)
 Mixed carcinoma, n (%) 2(1.3%) 10(2.5%)
 Others, n (%) 1(0.6%) 6(1.5%)
Tumor differentiation
 Well, n (%) 43(27.0%) 75(18.6%) <0.001 (χ2= 16.457)
 Moderate, n (%) 103(64.8%) 210(52.0%)
 Poor, n (%) 9(5.7%) 70(17.3%)
Muscular infiltration
 Endometrium, n (%) 25(15.7%) 59(14.6%) 0.969 (χ2= 0.072)
 <1/2 muscular layer, n (%) 97(61.0%) 215(53.2%)
 ≥1/2 muscular layer, n (%) 29(18.2%) 63(15.6%)
Lymphovascular invasion
 Absent, n (%) 125(78.6%) 280(69.3%) 0.583 (χ2= 0.436)
 Present, n (%) 20(12.6%) 54(13.4%)
Perineural invasion
 Absent, n (%) 143(89.9%) 326(80.7%) 0.557 (χ2= 1.312)
 Present, n (%) 0(0) 3(0.7%)
Disease stage
 I, n (%) 138(86.8%) 279(69.1%) 0.019 (χ2= 9.796)
 II, n (%) 5(3.1%) 22(5.4%)
 III, n (%) 12(7.5%) 57(14.1%)
 IV, n (%) 4(2.5%) 16(4.0%)

Abbreviations: dMMR, mismatch repair-deficient; POLE, DNA polymerase epsilon; NSMP, no specific molecular profile.